All In Biotech

Drug Trial Radar · NCT04819568

Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.

Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

310

Planned (sponsor's estimate)

Start

Jun 25, 2021

Primary completion

Mar 19, 2022

Study completion Mar 19, 2022

Sponsor

Lead sponsor
Institute of Liver and Biliary Sciences, IndiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Septic shock is a major life-threatening vasodilatory shock. Vasopressor form a crucial pharmacotherapeutic option and have long been used as the first and foremost recommended therapy.(1) However, some patients may remain refractory to catecholamine, which is also known as catecholamine-resistant septic shock.(2, 3) High-dose catecholamine therapy may lead to potential side effects such as increased myocardial oxygen consumption, lethal arrthymias, and even the high risk of mortality. (4)Therefore, newer alternatives like dopamine, dobutamine, somatostatin, and terlipressin are also used. Cirrhosis is a state of hyperdynamic circulation, which worsens with the onset of infection. In septic shock, there is relative deficiency of vasopressin. (13) The mortality of septic shock in these patients still remains extremely high. Terlipressin is a synthetic vasopressin analogue with greater selectivity for the V1-receptors.(5) In cirrhotics with septic shock, terlipressin has been used either as a continuous intravenous infusion or as intravenous boluses. However, at present none of studies reveal which would be a better mode of administration in cirrhotics with septic shock considering the reversal of hemodynamics and safety of patients.

Conditions

  • Liver Cirrhosis

Interventions

  • TerlipressinDrug

    Terlipressin Bolus Max dose 2 mg/24 hr.i.e 0.5 mg qid

  • Standard of CareOther

    Standard of Care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reversal of shockTime frame: 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Liver & Biliary Sciences

    New Delhi, National Capital Territory of Delhi, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.